PhageoteX is developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria which are highly resistant to antibiotics against chronic human diseases including UTI (Urinary tract infections) and skin infections (cellulitis, Leprosy, Boils, Impetigo). We are also providing phage cocktails to treat colibacillosis infections in poultry and mastitis in cattle. PhageoteX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.
We establish MDR profile for pathogenic bacteria, specific to each case, to determine the appropriate course of treatment.
We screen the pathogenic bacteria against a collection of phages and select only the most effective phages to create phage cocktails.
Infectious diseases, particularly MDR infections, are prevalent in places like Pakistan where access to proper sanitation is limited and excessive use of antibiotics is common. Our mission is to transform infection control with targeted, natural phage therapies that combat resistant bacteria, reduce antibiotic reliance, and support sustainable health for animals and humans.
We envision opening the first phage therapy center in Pakistan, to drive a global shift towards accessible phage therapy which restores health while preserving microbial balance.
PhageoteX is dedicated to providing safe, effective phage therapies by collaborating with healthcare providers to advance solutions against bacterial infections for people, animals, and the environment.
CEO & Founder
Co-Founder
Consultant Pathologist at AFIP
Helmholtz Zentrum Munich
Research Fellow ASAB
MS Industrial Biotechnology
Institute of Veterinary Bacteriology University of Bern, Switzerland
Phage Technology Center, Zurich University of Applied Biosciences, Switzerland
France
